Since PHF6 has a complementary function to RUNX1, it can be postulated that co-mutation of these two genes may show an additive detrimental effect on prognosis in addition to losing the tumor-suppressive role of PHF6. Thus, as shown by our analysis PHF6MT cases with RUNX1MT should be classified as a subset of AML with very poor survival outcomes. The gene discussed is PHF6; the disease is acute myeloid leukemia.